The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global anti-snoring treatment market reached a value of US$ 1.34 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 2.29 Billion by 2027, exhibiting a CAGR of 9.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Snoring refers to a noisy breathing sound coming through the nose or mouth of an individual, which is caused by the vibration of the soft tissues of the throat. It is medically treated using surgery or continuous positive airway pressure (CPAP), wherein a mask is worn over the nose or mouth and attached to a machine for delivering a constant flow of air into the nostrils. It can also be cured via lifestyle changes, such as maintaining body weight, relieving the nasal obstruction, changing sleep positions, and avoiding alcohol and sedating medications.
Rising technological advancements in devices that support anti-snoring treatment represent one of the key factors positively influencing the market. Moreover, long-term snoring increases the risk of developing fatigue, heart attacks, hypertension, stroke, type 2 diabetes, and decreased blood oxygen levels. Besides this, loud and frequent snoring is one of the signs of sleep apnea, which is a chronic condition characterized by shallow breaths or pauses in breathing during sleep. This condition can lead to glaucoma, cancer, and cognitive and behavioral disorders. In addition, people with sleep apnea have an increased threat of motor vehicle accidents as it can affect driving fitness. Consequently, there is a rise in the usage of anti-snoring apps, behavioral therapies, dental devices, tongue stabilizing devices (TSD), and mandibular advancing devices (MAD), also known as jaw advancing devices (JAD), to treat snoring, which is fueling the market growth. Furthermore, factors like sedentary lifestyles, unhealthy dietary habits, increasing tobacco and alcohol consumption, and the rising prevalence of sleep disorders among the masses are projected to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-snoring treatment market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on device type and distribution channel.
Breakup by Device Type:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Airway Management Inc., Apnea Sciences Corporation, Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., MEDiTAS Ltd., Medtronic plc, Mitsui Chemicals Inc., ResMed Inc., Rotech Healthcare Inc., SomnoMed, The Pure Sleep Company and Tomed GmbH.
|Base Year of the Analysis||2021|
|Segment Coverage||Device Type, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Airway Management Inc., Apnea Sciences Corporation, Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., MEDiTAS Ltd., Medtronic plc, Mitsui Chemicals Inc., ResMed Inc., Rotech Healthcare Inc., SomnoMed, The Pure Sleep Company and Tomed GmbH.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at